Dementia and Aging

Date/Time: Thursday, October 8, 2020 - 3:00 PM – 5:00 PM
Track: Special Interest Group
Log in to Add to My Schedule


Abnormal deposits of aggregated tau protein have been recognized as a pathological hallmark of a large number of neurodegenerative disorders, collectively referred to as tauopathies. Although abnormal tau has been recognized histopathologically for years, recent advances in biofluid analysis and neuroimaging have allowed for in vivo exploration of soluble and aggregated forms of tau in preclinical and symptomatic phases of tauopathies. In parallel with these developments, novel experimental therapeutics targeting tau aggregation, phosphorylation, and spread have greatly increased, generating hopes for disease-modifying therapies in the future. Given the diversity in methods to measure tau related changes in neurodegenerative diseases, it is important to understand key differences between methods and how each can help to better understand tauopathies, including Alzheimers disease and frontotemporal dementia. Likewise, it is important to consider the differences between the tau-focused therapies under-development and in clinical trials, especially how they were developed and how they are being tested.


  • To distinguish between key differences in measures of soluble and aggregated tau.

  • Identify the current state of tau therapeutics.

  • Recognize important differences between tau, phosphorylated tau and how they relate to different tauopathies and amyloid pathology.


Accelerated rate of hippocampal atrophy 17-years prior to death in Alzheimer’s disease is linked to TAR DNA binding protein 43

Clinical and Research Applications of High Affinity Tau Imaging Agents

Heterogeneity in Dementia

History of seizures in Alzheimer’s Disease is associated with elevations in mTOR activity and neuropathology

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Results of the DIAN-TU Prevention Trial of Solanezumab and Ganteneruma